Top Markets
Coin of the day
Kadimastem Ltd Kadimastem Ltd

Kadimastem Ltd

KDST
Rank in Stocks #41018
Kadimastem Ltd is a biopharmaceutical company focused on pioneering... Kadimastem Ltd is a biopharmaceutical company focused on pioneering regenerative medical treatments. These therapies are developed using cells sourced from human embryonic stem cells, primarily targeting neurodegenerative diseases. Its development pipeline features AstroRx, a clinical-grade human astrocyte product currently undergoing Phase 1/2a clinical trials for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. Additionally, the company is advancing IsletRx, a clinical-grade pancreatic islet cell therapy intended for the treatment of diabetes. Incorporated in 2008, Kadimastem is headquartered in Ness Ziona, Israel.
Share Price
$12.16
Last synced: 2025-10-30
Market Cap
$50.98K
Change (1 day)
-0.10%
Change (1 year)
60.98%
Country
IL
Trade Kadimastem Ltd (KDST)

Category

Revenue for Kadimastem Ltd (KDST)
Revenue in Aug 2026 TTM: 0
According to Kadimastem Ltd latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Kadimastem Ltd from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$12.62B -
US
$6.02B -
NL
- -
CH
- -
KR
$10.11B -
BE